3 June 2025, Turin, Italy – The BRAINTEASER project marked its official conclusion with a high-profile final event held as a satellite session of ENCALS 2025, the leading European conference on Amyotrophic Lateral Sclerosis (ALS) research.
With over 90 participants joining both in-person and online, the session served as a powerful moment to showcase the project’s most impactful results — and to discuss how its legacy can continue to shape the future of digital health research for ALS and Multiple Sclerosis (MS).
The event, titled “BRAINTEASER Legacy: Data, Tools and Knowledge for Advancing Future Research in Digital Health,” brought together a distinguished panel of experts and project partners. Participants engaged in a dynamic afternoon of presentations and dialogue that reflected not only the technical success of the project but also the strong community it built.
Chaired by Natalia Allegretti from ECHAlliance – The Global Health Connector, the session featured key contributions from:
- Deirdre Murray (University of Dublin), who opened with a reflection on the transformative role of digital health technologies in ALS care.
- Maria Fernanda Cabrera Umpierrez (Universidad Politécnica de Madrid), BRAINTEASER Project Coordinator, who provided a comprehensive overview of the project’s vision and achievements.
“BRAINTEASER has shown that digital health innovation is not just about developing advanced technologies; it is about making them usable, ethical, and relevant to people’s lives. Our legacy lies in the tools we have built, the data we have shared, and the partnerships we have nurtured. We hope these foundations will continue to support research, clinical care, and patient empowerment after the project ends.” – Maria Fernanda Cabrera
- Barbara Di Camillo (University of Padova), Scientific Coordinator, who discussed the innovative AI models and integrated datasets used for patient stratification, prognosis prediction, and disease progression simulation.
“Within BRAINTEASER, by tackling the challenge of developing AI-based tools for clinical use, we’ve learned from each other, integrating diverse domains of expertise. In the process, we hope to have left a legacy of valuable data and knowledge for future model use and development.” – Barbara Di Camillo
- Umberto Manera (University of Turin), who presented real-world demonstrations of the Patient App and Healthcare Professional App developed through the project.
- Vincenzo Carbone, PhD (InSilicoTrials Technologies), who outlined the strategies for ensuring sustainability and future uptake of BRAINTEASER’s tools.
The audience actively contributed to the discussion, raising numerous insightful questions — a testament to the relevance and real-world impact of the project’s outcomes across clinical, research, and policy domains.
By aligning with other European initiatives like Precision ALS and MND-SWIFTT, the event also fostered valuable cross-project dialogue on the evolving role of AI in neurology and digital health.
BRAINTEASER’s approach — blending artificial intelligence, real-world data, and co-designed digital applications — has set a new standard for collaborative health research in neurodegenerative diseases. As the project concludes, its tools, datasets, and knowledge remain openly available to fuel future research and innovation.
About BRAINTEASER
BRAINTEASER (Bringing Artificial Intelligence Home for Neurodegenerative Diseases) is funded under the Horizon 2020 programme. The project aims to improve the lives of people with ALS and MS through data-driven, patient-centred digital solutions.
